-PTI India has an estimated 25 lakh gay population and about 7 per cent of them are HIV-infected, the government today told the Supreme Court. “The population of MSM (men who have sex with men) is estimated to be 25 lakh in India,” the government said in its affidavit filed in the court, citing figures of the National Aids Control programme. The affidavit, filed by the health ministry, said it is planning to...
More »SEARCH RESULT
Road to cheaper drugs by Rupali Mukherjee
The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper drugs for lifestyle diseases. More generic companies could invoke the compulsory licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »India's patent ruling on cancer may open door for cheaper HIV drugs
-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...
More »Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »